Last updated: October 12, 2026
Angiomax, the brand name for bivalirudin, is an injectable direct thrombin inhibitor developed by The Medicines Company for anticoagulation during percutaneous coronary intervention. Its commercial peak occurred before generic entry. U.S. generic bivalirudin competition began in 2015, sharply reducing branded revenue and weakening the product’s pricing power. Angiomax no longer has a meaningful branded exclusivity position, and its commercial market is now governed by generic hospital purchasing, formulary placement, supply reliability, and manufacturing economics.
What is Angiomax and how is it used?
Angiomax is a synthetic 20-amino-acid anticoagulant that directly inhibits thrombin. The FDA approved it in 2000 for use in patients undergoing percutaneous coronary intervention, including patients with or at high risk of heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome. The product is administered intravenously and is supplied as a lyophilized powder for reconstitution.
The main clinical and commercial attributes are:
| Attribute |
Angiomax |
| Active ingredient |
Bivalirudin |
| Drug class |
Direct thrombin inhibitor |
| Route |
Intravenous |
| Primary use |
Anticoagulation during PCI |
| Original sponsor |
The Medicines Company |
| U.S. approval |
2000 |
| Main competitors |
Unfractionated heparin, enoxaparin, generic bivalirudin |
| Current market status |
Generic-dominated hospital market |
| Biosimilar exposure |
None; bivalirudin is a chemically synthesized small molecule |
Bivalirudin competes primarily against inexpensive unfractionated heparin rather than against other branded specialty drugs. Clinical use has been influenced by bleeding outcomes, cath-lab protocols, hospital formularies, physician familiarity, and the cost differential between bivalirudin and heparin.
What was the commercial trajectory of Angiomax?
Angiomax generated substantial revenue for The Medicines Company during the period when it had limited direct competition and was positioned as a specialized anticoagulant for interventional cardiology.
The product benefited from several commercial drivers:
- Use in PCI procedures.
- Concern over heparin-induced thrombocytopenia.
- Adoption in hospitals seeking alternatives to unfractionated heparin.
- Reimbursement through hospital procedure economics.
- Clinical evidence supporting reduced bleeding in selected PCI populations.
- The Medicines Company’s focus on hospital-based acute-care products.
Reported Angiomax revenue remained above $300 million annually during its commercial peak. Generic competition began to erode sales materially after 2015.
| Period |
Financial development |
Market interpretation |
| 2000-2007 |
U.S. launch and expansion |
Product established in PCI and acute-care hospitals |
| 2008-2013 |
Peak commercial period |
Angiomax became The Medicines Company’s primary revenue source |
| 2014 |
High branded sales |
Revenue remained concentrated in Angiomax |
| 2015 |
Generic entry began |
Pricing and volume pressure emerged |
| 2016-2018 |
Steep decline in branded revenue |
Generic substitution and lower net pricing reduced sales |
| 2019-2020 |
Residual branded and product-portfolio revenue |
Angiomax was no longer the company’s principal growth asset |
| 2021 onward |
Generic bivalirudin market |
Branded Angiomax has limited commercial relevance |
The Medicines Company’s financial exposure to Angiomax was unusually concentrated. Before generic entry, the product accounted for most of the company’s revenue and financed development of other assets. The loss of exclusivity therefore affected not only Angiomax sales but also the company’s valuation, cash-generation profile, and strategic flexibility.
The Medicines Company was acquired by Novartis in 2020 in a transaction focused primarily on inclisiran, later marketed as Leqvio. The transaction did not represent a recovery of Angiomax’s branded economics. By that stage, Angiomax had already experienced substantial generic erosion. (The Medicines Company, 2015, 2016; Novartis, 2020)
When did Angiomax lose exclusivity?
Angiomax lost effective U.S. market exclusivity when generic bivalirudin products entered the market in 2015. The key product patent, U.S. Patent No. 5,196,404, covered bivalirudin and related compounds and reached the end of its effective term in the mid-2010s.
The practical exclusivity timeline was:
| Event |
Approximate date |
Effect |
| FDA approval |
2000 |
Branded launch |
| Core composition patent term |
Mid-2010s |
Principal protection ended |
| First generic approvals and launches |
2015 |
Direct price competition |
| Branded sales erosion |
2015-2017 |
Rapid decline in market share and net revenue |
| Current status |
2020s |
Generic-dominated market |
Patent-term extensions, pediatric exclusivity, and regulatory exclusivity can affect the precise date on which a product becomes vulnerable. For Angiomax, those protections did not preserve a durable commercial monopoly after generic bivalirudin approvals.
What patents protect Angiomax?
The principal patent estate was historically based on composition-of-matter and use protection rather than on a durable device or complex-delivery platform.
Core composition patent
U.S. Patent No. 5,196,404 covered bivalirudin-related compounds and was the most commercially important patent associated with Angiomax. Its expiration removed the primary barrier to abbreviated new drug application competition.
Method-of-use patents
The Angiomax estate also included patents and regulatory listings associated with use in PCI and anticoagulation. Method-of-use claims can remain relevant after composition patents expire, but their commercial value is limited when:
- The principal clinical use is widely known.
- Hospitals can use generic product for non-patented indications.
- Generic labels may employ carve-outs.
- Prescribers and hospital pharmacists can substitute products under institutional protocols.
Method-of-use patents did not preserve Angiomax’s pre-2015 pricing structure.
Formulation and manufacturing protection
Angiomax is an injectable peptide drug supplied as a powder for reconstitution. Formulation and manufacturing know-how can create technical barriers, including:
- Peptide synthesis and purification.
- Control of impurities and degradation products.
- Sterile fill-finish operations.
- Stability during storage.
- Validated reconstitution performance.
- Consistent dose delivery in hospital settings.
These barriers are operational rather than durable exclusivity barriers. Generic manufacturers that meet FDA quality and bioequivalence requirements can compete without reproducing every aspect of the branded manufacturing process.
What is the Orange Book status of Angiomax?
Angiomax’s Orange Book significance has declined since generic bivalirudin entered the market. The relevant Orange Book issues historically included:
- Listing of patents associated with bivalirudin.
- Patent certifications submitted by generic applicants.
- Potential Paragraph IV challenges.
- Method-of-use claims and label carve-outs.
- Expiration dates controlling the timing of generic approval or launch.
The Orange Book does not create a continuing commercial barrier after listed patents expire or lose practical enforceability. For Angiomax, the principal market event was the transition from an innovator product with meaningful listed-patent protection to an off-patent injectable with multiple generic suppliers. (U.S. Food and Drug Administration, 2024a)
Which companies challenged Angiomax patents?
Generic drug companies pursued U.S. approval for bivalirudin products as the principal route to market entry. Publicly documented generic competition involved manufacturers of injectable hospital products, including firms such as Dr. Reddy’s Laboratories and other ANDA sponsors.
The principal legal mechanism was the Paragraph IV certification under the Hatch-Waxman Act. A Paragraph IV filing asserts that a listed patent is invalid, unenforceable, or not infringed. Such a filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval.
For Angiomax, the relevant competitive outcome was generic availability rather than a long-term litigation settlement that preserved brand exclusivity. After generic approvals, the commercial dispute shifted from patent enforcement to contracting, hospital conversion, supply, and price.
What patent litigation affected Angiomax?
The most important Angiomax litigation involved patent challenges directed at the core bivalirudin intellectual-property estate. The Medicines Company sought to protect the product through listed patents and enforcement actions against ANDA applicants.
The litigation strategy had limited long-term value because:
- The core patent estate approached expiration.
- Generic applicants had a clear economic incentive to enter.
- Bivalirudin was an injectable small molecule rather than a biologic with complex interchangeability barriers.
- Hospital buyers were highly sensitive to price.
- Generic manufacturers could compete through standard ANDA pathways.
A patent dispute can delay entry, but it cannot permanently protect a product once the principal composition patent expires and alternative claims do not support a durable injunction or settlement period.
Were there Angiomax settlement agreements?
Generic pharmaceutical patent settlements may include launch dates, licenses, supply arrangements, or other commercial terms. The public record does not support treating Angiomax as a product with a major, long-duration settlement barrier comparable to some blockbuster oral drugs.
The commercially relevant result was generic entry during the mid-2010s. Any settlement arrangements associated with individual ANDA applicants did not prevent the broader loss of branded pricing power.
How strong is the Angiomax patent estate today?
The Angiomax patent estate is weak as a source of current commercial exclusivity.
| Protection category |
Current strength |
| Composition of matter |
Expired or commercially exhausted |
| PCI method of use |
Limited practical protection |
| Formulation |
Limited unless tied to an unexpired, enforceable claim |
| Manufacturing process |
Technical know-how, not a broad market monopoly |
| Device or delivery system |
Not a major exclusivity platform |
| Regulatory exclusivity |
Expired |
| Biosimilar barrier |
Not applicable |
The product’s remaining defensibility is operational. A manufacturer may gain share through dependable supply, low acquisition cost, validated sterile manufacturing, and hospital contracting. Those factors can produce commercial advantage without creating patent-based pricing power.
What generic entry risks exist for Angiomax?
Generic entry risk has already materialized. The current market risks are more accurately described as generic pricing and supply risks.
Price compression
Generic bivalirudin competes in a hospital purchasing environment where pharmacy departments and group purchasing organizations negotiate aggressively. Branded price premiums are difficult to maintain when the active ingredient, route, dosage form, and clinical use are comparable.
Supplier concentration
Injectable products can experience shortages because of manufacturing failures, sterile-facility constraints, raw-material problems, or regulatory remediation. A generic supplier with reliable availability can win share even without the lowest nominal price.
Formulary substitution
Hospitals can establish protocols that favor generic bivalirudin or unfractionated heparin. Once a product is embedded in a cath-lab protocol, switching costs can work in either direction, but they do not protect the Angiomax brand in the absence of a meaningful price or clinical advantage.
Therapeutic substitution
Heparin remains a major competitive constraint because it is inexpensive, familiar, and widely available. Bivalirudin demand is therefore sensitive to institutional anticoagulation protocols and clinical evidence, not only to generic substitution.
How does Angiomax compare with heparin and competing anticoagulants?
| Product |
Type |
Main advantage |
Main commercial constraint |
| Angiomax |
Branded bivalirudin |
Established PCI use and predictable direct thrombin inhibition |
Patent expiry and generic competition |
| Generic bivalirudin |
Generic direct thrombin inhibitor |
Lower acquisition cost with the same active ingredient |
Supply and manufacturing quality |
| Unfractionated heparin |
Indirect thrombin inhibitor |
Very low cost and broad hospital familiarity |
Monitoring requirements and HIT concerns |
| Enoxaparin |
Low-molecular-weight heparin |
Established anticoagulant use |
Less direct fit for all PCI protocols |
| Argatroban |
Direct thrombin inhibitor |
Important option in HIT |
Different use profile and dosing requirements |
Angiomax’s strongest clinical-commercial position was in patients for whom clinicians valued an alternative to heparin, particularly where heparin-induced thrombocytopenia was a concern. Its weakest position was routine use where hospitals could achieve acceptable outcomes with low-cost heparin.
What was the revenue exposure from Angiomax?
Angiomax created concentrated revenue exposure for The Medicines Company. The company’s filings identified Angiomax as its primary commercial product before generic competition. Revenue declined materially after the first generic launches, and the company’s financial profile shifted toward pipeline development, licensing, and other acute-care products.
The main financial effects were:
- Lower product revenue.
- Reduced gross margin.
- Loss of operating leverage from a mature hospital sales force.
- Greater dependence on pipeline assets.
- Lower strategic value of the Angiomax franchise.
- Increased importance of business development and licensing transactions.
The acquisition of The Medicines Company by Novartis reflected the value of the company’s later-stage inclisiran program rather than a recovery of Angiomax economics. Angiomax was a declining legacy asset by the time of the transaction. (Novartis, 2020)
What is the FDA regulatory status of Angiomax and generic bivalirudin?
The FDA-approved reference product is Angiomax, while generic manufacturers market bivalirudin for injection through the ANDA pathway. FDA approval depends on pharmaceutical equivalence, bioequivalence where applicable, and compliance with quality and manufacturing requirements.
Because bivalirudin is a chemically synthesized small molecule, it is not subject to the biosimilar framework used for biologic products. The relevant regulatory risks are:
- ANDA approval and patent certification.
- Sterile manufacturing compliance.
- Product quality and stability.
- Drug-shortage management.
- Labeling and indication consistency.
- Hospital substitution and purchasing contracts.
There is no biosimilar pipeline risk for Angiomax. The competitive threat is generic substitution. (U.S. Food and Drug Administration, 2024b)
What licensing deals affected the Angiomax market?
The Medicines Company used partnerships, licensing transactions, and acquisitions to build a hospital-focused portfolio around Angiomax and related acute-care products. These arrangements helped commercialize assets and extend the company’s business beyond one product, but they did not eliminate Angiomax’s exposure to patent expiry.
The major strategic transaction relevant to the product’s financial trajectory was Novartis’s acquisition of The Medicines Company. The transaction transferred control of a company whose value had moved away from Angiomax and toward inclisiran. That shift illustrates the commercial lifecycle of Angiomax: launch asset, revenue anchor, loss-of-exclusivity product, and legacy hospital brand.
What generic launch scenarios remain for Angiomax?
Three commercial scenarios define the current market:
Low-price generic market
Multiple suppliers compete primarily on contract price. Angiomax has little ability to command a premium, and generic bivalirudin captures most demand.
Supply-constrained generic market
A manufacturing disruption at one or more suppliers creates temporary price increases or allocation opportunities. The benefit accrues to available generic suppliers rather than to a durable Angiomax monopoly.
Clinical niche market
Bivalirudin retains demand in selected PCI cases, including patients with heparin-induced thrombocytopenia or institutions with established bivalirudin protocols. This supports ongoing unit demand but does not restore branded exclusivity.
What is the geographic coverage of Angiomax patents?
The principal commercial value was concentrated in the United States, where The Medicines Company generated most of its Angiomax revenue and where FDA approval and Orange Book listings governed generic entry.
Outside the United States, protection depended on national patent terms, local regulatory approvals, reimbursement systems, and hospital procurement. European and other markets were also exposed to patent expiry and generic competition, although launch timing and market penetration varied by country.
There is no current indication that geographic patent coverage creates a material global barrier to generic bivalirudin. The relevant business issues are local regulatory approval, tender participation, supply reliability, and hospital contracting.
Key Takeaways
- Angiomax is the brand name for bivalirudin, an intravenous direct thrombin inhibitor used mainly during PCI.
- The Medicines Company relied heavily on Angiomax revenue before generic entry.
- U.S. generic competition began in 2015 and caused a substantial decline in branded sales.
- The core bivalirudin patent estate no longer provides meaningful current exclusivity.
- Method-of-use, formulation, and manufacturing considerations do not recreate the former branded monopoly.
- Angiomax faces generic substitution, low-cost heparin competition, and hospital formulary pressure.
- No biosimilar risk applies because bivalirudin is a chemically synthesized small molecule.
- Current commercial value is concentrated in generic supply, manufacturing quality, and hospital contracting.
- Novartis’s acquisition of The Medicines Company was driven by inclisiran, not by a recovery of Angiomax’s branded franchise.
- Angiomax is best analyzed as a mature, off-patent hospital injectable with limited branded revenue potential.
FAQs About Angiomax Patent Expiry and Market Competition
Is Angiomax still sold as a branded drug?
Generic bivalirudin has replaced most of the commercial demand historically associated with branded Angiomax. The brand has limited current market significance compared with generic products.
Is bivalirudin interchangeable with Angiomax?
Generic bivalirudin contains the same active ingredient and is approved through the FDA’s generic-drug pathway. Hospital substitution is governed by institutional policy, purchasing contracts, and applicable state rules.
Does Angiomax have a biosimilar competitor?
No. Biosimilar regulation applies to biologic products. Bivalirudin is a chemically synthesized peptide drug and is subject to generic-drug regulation.
Why do hospitals still use bivalirudin after patent expiry?
Hospitals use bivalirudin where clinical protocols, heparin-induced thrombocytopenia concerns, physician preference, or procedural considerations support direct thrombin inhibition.
Can a new formulation revive Angiomax exclusivity?
A new formulation could obtain patent protection only if it satisfies patentability and other legal requirements. A reformulation would need a meaningful technical or clinical advantage to overcome the low-cost generic market.
References
The Medicines Company. (2015). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2014. U.S. Securities and Exchange Commission.
The Medicines Company. (2016). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2015. U.S. Securities and Exchange Commission.
Novartis AG. (2020). Novartis completes acquisition of The Medicines Company. Novartis.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. FDA.
